Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A clinician-level guide to preventing, recognizing, and managing adverse events with rapid-acting insulin analogs (lispro, aspart, glulisine, faster aspart, inhaled insulin). Includes hypoglycemia protocols, injection-site reactions, and dosing frameworks.
Read clinical reviewA comprehensive drug-drug interaction table and class review for rapid-acting insulin analogs (lispro, aspart, glulisine, faster aspart). Pharmacokinetics, DDI mechanisms, clinical management strategies, and dosing guidance for prescribers and pharmacists.
Read clinical reviewEvidence-based monitoring protocols for rapid-acting insulin analogs including lispro, aspart, and glulisine. Covers baseline labs, glycemic targets, hypoglycemia surveillance, and injection-site assessment for prescribers and pharmacists.
Read clinical reviewA prescriber-level playbook for billing, coding, and navigating prior authorization for rapid-acting insulin analogs including lispro, aspart, and glulisine.
Read clinical reviewA prescriber-level monograph covering the pharmacology, clinical trial data, dosing, safety, and guideline recommendations for all rapid-acting insulin analogs including lispro, aspart, glulisine, and ultra-rapid formulations.
Read clinical reviewA clinical guide to choosing among lispro, aspart, glulisine, faster aspart, and ultra-rapid lispro for prandial insulin coverage. Written at MD/PharmD level with head-to-head trial data, dosing nuances, and practical switching guidance.
Read clinical reviewA prescriber-level review of rapid-acting insulin analogs (lispro, aspart, glulisine, ultra-rapid formulations) across pediatric, pregnant, elderly, and renal/hepatic-impaired populations, with dosing guidance and key trial data.
Read clinical reviewA prescriber-level guide to rapid-acting insulin analog pharmacology, prandial titration protocols, dose tapering strategies, and clinical decision frameworks for lispro, aspart, and glulisine.
Read clinical review